1. Home
  2. Weight Management & Metabolism
  3. CagriSema
CagriSema
Weight Management

CagriSema

Cagrilintide + semaglutide · Investigational combination

An investigational once-weekly combination of cagrilintide and semaglutide.

Price confirmed by your advisor.

Available on request in Canada

Ask an advisor
Non-binding request. An advisor contacts you and the partner pharmacy checks whether and how it can proceed. A valid prescription, or an assessment through an authorized telemedicine service, may be required.
  • Partner pharmacy
  • Personal assistance
  • Discreet delivery

Shipping & Delivery

  • Normally dispatched within 24 hours of payment confirmation.
  • UPS Express · C$25 · Approx. 7–9 business days
  • Registered Mail · C$15 · Approx. 14–20 business days

For research use only.

Not intended for human or animal consumption, nor for medical, personal or diagnostic use. By purchasing this product, you confirm that you are qualified to handle research materials.

Research status

What is known so far

CagriSema combines cagrilintide, a long-acting amylin analog, with the GLP‑1 receptor agonist semaglutide in a once-weekly injection. It is being studied in clinical trials and has no marketing authorization.

It has no marketing authorization as a medicine in this market. This page summarizes the state of research and does not describe proven clinical benefits.

Documents

Product information

Patient information leafletNot available: not an authorized medicine
Summary of Product CharacteristicsNot available: not an authorized medicine
Related
Weight Management
  • Orforglipron
    Orforglipron

    Orforglipron

    Status under review · information only

    On request

  • Cagrilintide
    Cagrilintide

    Cagrilintide

    Research compound · information only

    On request

  • Victoza
    Liraglutide

    Victoza

    Pen · 1, 2 or 3 pens

    On request

    fromC$170